Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT

We report on patients (pts) with R/R large B cell NHL treated with liso-cel in the outpatient setting in TRANSCEND NHL 001 (NCT02631044) and two phase 2 studies ( ≥3rd-line therapy: OUTREACH, NCT03744676; 2nd-line TNE: PILOT, NCT03483103).

https://www.bbmt.org/article/S1083-8791(19)30955-3/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Carlos R. Bachier, M. Lia Palomba, Jeremy S. Abramson, Charalambos Andreadis, Alison Sehgal, John Godwin, Gerhard C Hildebrandt, Tanya Siddiqi, Don Stevens, Thalia Farazi, Ana Kostic, Nikolaus S Trede, Lei Wang, James Lymp, Tennille Thelen, Ken Ogasawara, Tags: 29 Source Type: research